{"id":70721,"date":"2026-07-27T21:10:55","date_gmt":"2026-07-27T13:10:55","guid":{"rendered":"https:\/\/flcube.com\/?p=70721"},"modified":"2026-07-27T21:10:56","modified_gmt":"2026-07-27T13:10:56","slug":"sino-biopharmaceutical-and-tempo-scan-form-jv-to-commercialize-innovative-drugs-in-indonesia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70721","title":{"rendered":"Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sino Biopharmaceutical Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1177:HKG\">HKG: 1177<\/a>) and <strong>PT Tempo Scan Pacific Tbk<\/strong> (&#8220;Tempo Scan&#8221;) announced the official signing of a joint venture agreement to establish <strong>PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI)<\/strong> in Indonesia. Under the agreement, <strong>Sino Biopharmaceutical will hold a 51% stake<\/strong> in TCBI, while <strong>Tempo Scan will hold the remaining 49%<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-strategic-partnership-framework\" class=\"wp-block-heading\">Strategic Partnership Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partners<\/strong><\/td><td>Sino Biopharmaceutical Limited (HKG: 1177) \/ PT Tempo Scan Pacific Tbk<\/td><\/tr><tr><td><strong>JV Entity<\/strong><\/td><td>PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI)<\/td><\/tr><tr><td><strong>Ownership Structure<\/strong><\/td><td>Sino Biopharmaceutical: 51% \/ Tempo Scan: 49%<\/td><\/tr><tr><td><strong>Geographic Focus<\/strong><\/td><td>Indonesia<\/td><\/tr><tr><td><strong>Primary Activities<\/strong><\/td><td>Registration, clinical development, medical affairs, market access, and commercialization of innovative drugs and specialty pharmaceuticals<\/td><\/tr><tr><td><strong>Future Considerations<\/strong><\/td><td>Evaluation of local manufacturing opportunities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-capabilities-integration\" class=\"wp-block-heading\">Strategic Rationale &amp; Capabilities Integration<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sino Biopharmaceutical Contribution:<\/strong> Innovative drug R&amp;D expertise, robust product pipeline, and international operations experience<\/li>\n\n\n\n<li><strong>Tempo Scan Contribution:<\/strong> Local manufacturing capabilities, regulatory affairs expertise, market access networks, sales and marketing infrastructure, and nationwide distribution across Indonesia&#8217;s 17,000+ islands<\/li>\n\n\n\n<li><strong>Synergy Model:<\/strong> Combines global innovation with local market penetration capabilities to address Indonesia&#8217;s underserved specialty pharmaceutical needs<\/li>\n\n\n\n<li><strong>Market Entry Strategy:<\/strong> Leverages Tempo Scan&#8217;s established regulatory relationships and distribution channels to accelerate time-to-market for Sino Biopharmaceutical&#8217;s pipeline products<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-indonesia-pharmaceutical-market-context\" class=\"wp-block-heading\">Indonesia Pharmaceutical Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Size:<\/strong> Indonesia represents Southeast Asia&#8217;s largest pharmaceutical market with estimated $9.2 billion in annual sales and 8-10% annual growth<\/li>\n\n\n\n<li><strong>Population Access:<\/strong> Serves 275 million people with increasing demand for innovative therapies and specialty medicines<\/li>\n\n\n\n<li><strong>Regulatory Environment:<\/strong> BPOM (Indonesia&#8217;s FDA equivalent) has streamlined approval pathways for innovative drugs through recent reforms<\/li>\n\n\n\n<li><strong>Healthcare Infrastructure:<\/strong> Expanding universal healthcare coverage (JKN) creating increased demand for quality pharmaceuticals<\/li>\n\n\n\n<li><strong>Local Manufacturing Incentives:<\/strong> Government policies favoring domestic production with tax incentives and import restrictions on certain drug categories<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-impact-amp-growth-outlook\" class=\"wp-block-heading\">Strategic Impact &amp; Growth Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Acceleration:<\/strong> TCBI expected to advance 8-12 innovative drug candidates through Indonesian registration over the next 3 years<\/li>\n\n\n\n<li><strong>Revenue Projection:<\/strong> Targeting $150-200 million in annual revenue by year 5 of operations<\/li>\n\n\n\n<li><strong>Market Positioning:<\/strong> Positions Sino Biopharmaceutical as a leading Chinese innovator in Southeast Asia&#8217;s largest pharmaceutical market<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> First-mover advantage among Chinese biopharma companies establishing dedicated Indonesian commercial operations<\/li>\n\n\n\n<li><strong>Long-term Vision:<\/strong> Potential platform for expansion into other ASEAN markets leveraging the Indonesia hub model<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the joint venture formation, strategic objectives, market opportunities, and financial projections. Actual results may differ due to risks including regulatory approvals, market acceptance, competitive dynamics, and geopolitical factors affecting Indonesia-China business relations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sino Biopharmaceutical Limited (HKG: 1177) and PT Tempo Scan Pacific Tbk (&#8220;Tempo Scan&#8221;) announced the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":70722,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[908,313],"class_list":["post-70721","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hkg-1177","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) and PT Tempo Scan Pacific Tbk (&quot;Tempo Scan&quot;) announced the official signing of a joint venture agreement to establish PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI) in Indonesia. Under the agreement, Sino Biopharmaceutical will hold a 51% stake in TCBI, while Tempo Scan will hold the remaining 49%.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70721\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia\" \/>\n<meta property=\"og:description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) and PT Tempo Scan Pacific Tbk (&quot;Tempo Scan&quot;) announced the official signing of a joint venture agreement to establish PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI) in Indonesia. Under the agreement, Sino Biopharmaceutical will hold a 51% stake in TCBI, while Tempo Scan will hold the remaining 49%.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70721\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-27T13:10:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-27T13:10:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2702.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70721#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70721\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia\",\"datePublished\":\"2026-07-27T13:10:55+00:00\",\"dateModified\":\"2026-07-27T13:10:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70721\"},\"wordCount\":412,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70721#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2702.webp\",\"keywords\":[\"HKG: 1177\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70721#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70721\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70721\",\"name\":\"Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70721#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70721#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2702.webp\",\"datePublished\":\"2026-07-27T13:10:55+00:00\",\"dateModified\":\"2026-07-27T13:10:56+00:00\",\"description\":\"Sino Biopharmaceutical Limited (HKG: 1177) and PT Tempo Scan Pacific Tbk (\\\"Tempo Scan\\\") announced the official signing of a joint venture agreement to establish PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI) in Indonesia. Under the agreement, Sino Biopharmaceutical will hold a 51% stake in TCBI, while Tempo Scan will hold the remaining 49%.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70721#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70721\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70721#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2702.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2702.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70721#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia - Insight, China&#039;s Pharmaceutical Industry","description":"Sino Biopharmaceutical Limited (HKG: 1177) and PT Tempo Scan Pacific Tbk (\"Tempo Scan\") announced the official signing of a joint venture agreement to establish PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI) in Indonesia. Under the agreement, Sino Biopharmaceutical will hold a 51% stake in TCBI, while Tempo Scan will hold the remaining 49%.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70721","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia","og_description":"Sino Biopharmaceutical Limited (HKG: 1177) and PT Tempo Scan Pacific Tbk (\"Tempo Scan\") announced the official signing of a joint venture agreement to establish PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI) in Indonesia. Under the agreement, Sino Biopharmaceutical will hold a 51% stake in TCBI, while Tempo Scan will hold the remaining 49%.","og_url":"https:\/\/flcube.com\/?p=70721","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-27T13:10:55+00:00","article_modified_time":"2026-07-27T13:10:56+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2702.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70721#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70721"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia","datePublished":"2026-07-27T13:10:55+00:00","dateModified":"2026-07-27T13:10:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70721"},"wordCount":412,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=70721#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2702.webp","keywords":["HKG: 1177","Sino Biopharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70721#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70721","url":"https:\/\/flcube.com\/?p=70721","name":"Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=70721#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=70721#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2702.webp","datePublished":"2026-07-27T13:10:55+00:00","dateModified":"2026-07-27T13:10:56+00:00","description":"Sino Biopharmaceutical Limited (HKG: 1177) and PT Tempo Scan Pacific Tbk (\"Tempo Scan\") announced the official signing of a joint venture agreement to establish PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI) in Indonesia. Under the agreement, Sino Biopharmaceutical will hold a 51% stake in TCBI, while Tempo Scan will hold the remaining 49%.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70721#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70721"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=70721#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2702.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2702.webp","width":1080,"height":608,"caption":"Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70721#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2702.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70721","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70721"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70721\/revisions"}],"predecessor-version":[{"id":70723,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70721\/revisions\/70723"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/70722"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70721"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70721"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70721"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}